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THE BIOCHEMISTRY OF LYMPHOCYTES FROM PATIENTS 
WITH CHRONIC LYMPHOCYTIC LEUKEMIA
CHAPTER I 
INTRODUCTION
Chronic Lymphocytic Leukemia 
The clinical manifestations of leukemia have been known since the 
time of Hippocrates, although the full description of the disease was not 
published until 1845. In that year, Bennett (1) and Virchow (2), working 
independently, reported that patients who, at autopsy, were found to have 
marked changes in the blood also had unusually large livers and spleens. 
Bennett described the blood as having "great numbers of pus and lymph 
cells", whereas Virchow recognized an inversion of the usual numbers of 
red and white cells. Thus, Virchow's concept of the predominance of the 
white blood cells rather than "pus" cells has become the hallmark of diag­
nosis, and his proposed name for the disease "Weisses Blut or Leukamie" 
has been adopted.
After their definitive work, it became apparent that many earlier 
reports in the literature were descriptive of this same process (3,4). 
Within the next 45 years many additional cases were reported in the litera­
ture, but it was not until the year 1891 when Ehrlich introduced specific 
staining techniques to differentiate cell types that a histological basis
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for classification and accurate diagnosis could be made.
Classification was based upon the following: a) whether the
disease was acute or chronic, and b) what type of cell was predominant in 
the peripheral blood. The disease process explored in this study was chronic 
lymphocytic leukemia (CLL) and was recognized as a protracted disease with 
an accumulation of small, mature lymphocytes in the peripheral blood and 
lymphoid tissues. Within this broad definition, several types of CLL have 
been recognized (5), a benign form in which the patient has little distress, 
an aggressive form in which the lymphocytes rapidly infiltrate the peri­
pheral lymphoid tissues and bone marrow, and an unusual form of chronic 
dermatologie disturbance. The patients in this study had either the benign 
or aggressive form of disease; the dermatologie form was not studied.
Epidemiological studies of CLL indicated that the ages of greatest 
occurrence were between 45 and 54 years in America and England, and the 
disease occurred more frequently in males (74%) than in females (26%) (6,7). 
Studies of the geographical distribution of the disease indicated wide­
spread occurrence with an increased incidence in Israel, the United States, 
Denmark and among the Jews in New York City (8). In contrast, there was 
virtually no incidence of CLL in Japan (9) and significantly reduced in­
cidence among Chinese (10) and New Zealand Maoris (11).
Many etiologic agents have been proposed at one time or another 
as the primary causative agent of CLL; and although trauma, parasites, 
bacteria, and viruses have been suggested, there were no unequivocal data 
supporting any one agent. The earliest report of an etiologic agent 
suspected the small bacillus (12), this was followed by Osterwald’s 
report of the micrococcus (13) and Jousset's report of the coccobacillus
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(14). Since these initial reports, staphylococcus (15), streptococcus (16), 
diphtheroid bacillus (17), tubercle bacillus (18), Bacillus typhosus (19), 
Bacillus paratyphosus B (20), Pneumococcus (21) and Bacillus proteus (22) 
have all be suspected of causing CLL, however Forkner (23) concluded 30 
years ago that these agents were not the primary causes of leukemia.
A second possible etiologic agent suggested was trauma, specifi­
cally fractures, which was reported by Norikoff in 1933 (24), but, subse­
quently, this has not been found to be of significance in other studies.
In 1933 Luisada suggested that the etiologic agent was malaria (25), after 
Loesch (26) had noted the development of CLL in a patient who had been 
treated for syphilis with an inoculation of the malaria-causing parasite. 
This was later discounted because of the failure to substantiate it in 
other cases of CLL or malaria. Studies which were designed to assess the 
effects of bacterial, parasitic and viral agents should be evaluated care­
fully due to the severe complications of tuberculous, viral, fungal or 
acute bacterial infections which were commonly found in patients with all 
forms of leukemia, including CLL.
Radioactive substances have also been suggested as the etiologic 
agent in CLL. Jagic ejt al. (27) reported, in 1911, the occurrence of 
"lymphogeneous leukemia" in a patient who had worked with roentgen rays 
for eight years. In 1945, two atomic bombs were dropped on Hiroshima 
and Nagasaki, thus providing the largest experiment to assess the effects 
of one dose of ionizing radiation on a human population. A significant 
increase in leukemia was evident three years later, especially in persons 
within 2,000 meters of the site of detonation (hypocenter) (28). How­
ever, chronic granulocytic leukemia was the most common type found, acute 
lymphoblastic the second most common type and CLL was found in merely
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negligible quantities in the exposed population. In a recent report of 
the 13 cases of CLL found in the Japanese population since 1945 (29), it 
was shown that only, five of these patients had been within the Nagasaki 
city limits at the time of detonation. These five had been at a distance 
greater than 3,000 meters from hypocenter, and the calculated dose of 
radiation was less than one roentgen. These data and those of Cronkite 
(30) strongly suggested that ionizing radiation was not the primary etio­
logic agent in CLL.
The most promising areas of reasearch in elucidating the primary 
etiologic agent in CLL were virology and genetics. Virus particles have 
been found as the mode of transmission of the acute leukemias of fowl (31) 
and mice (32), and subsequently two models of genetic transmission have 
been suggested. The first of these was vertical transmission from one 
generation to the next of an altered genome or the potential for an 
altered genome carried in the germ cells (33). The second was the hori­
zontal transmission of the viral genome from an infected host to a "poten­
tial" host with the altered genome transmitted to the somatic cell progeny.
In both models it was essential that the viral genome become in­
corporated into the host deoxyribonucleic acid (DNA) in order for it to 
be stably transmitted to the progeny cells,, For DNA viruses, incorporation 
into host DNA was facilitated by cellular DNA polymerases; in contrast, 
ribonucleic acid (ENA) viruses posed many conceptual problems as to the 
mode of genetic transmission. Recently, however, an RNA-dependent DNA 
polymerase has been found which used RNA as a template to transcribe a 
complementary copy of DNA (34,35) which was then converted to double­
stranded DNA, cleaved to 7 S pieces and integrated into the host DNA 
during replication of the host genome. It was believed that this
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provided for the stable transmission of the viral genome, either fully or 
in part, to progeny cells. This RNA-dependent DNA polymerase appeared to 
be associated with oncogenic viruses (36), non-oncogenic viruses (37) and 
a wide range of host cells including lymphocytes (38).
The role of genetic predisposition in CLL has been suggested by 
many authors (39), and two lines of evidence supported this hypothesis.
First, there was an increased tendency for leukemia to occur in kinships, 
especially sibships (40). Parental consanguinity with an increased in­
cidence of CLL has been observed (41). In one family studied, there was 
an increase in immune defects in those sibs which did not have leukemia 
(42). The second line of evidence was from the epidemiological studies of 
the geographical distribution of CLL. These studies indicated that the 
almost negligible incidence of CLL in Japan was quite striking since in 
Japan 4 to 5% of the marriages were between first cousins (43), and there 
was a lower frequency of CLL in Japanese who were living in the United 
States than in the non-Japanese population (44). This suggested that an 
undetermined alteration of metabolism was controlled by predisposing 
genetic factors, and that the lack of genetic mixing has had profound 
effects on the incidence of the disease.
Cell Culture
Non-stimulated Lymphocytes 
Biochemistry. Leukemia cells were first cultured in 1914 (45), 
and in 1929 Timofej ewsky and Benewolenskaja (46) showed that CLL lympho­
cytes could be maintained in cell culture. However, due to the many cell 
types present in their culture system, it was impossible to draw any conclu­
sions about the "physiologic or diagnostic value of the system" (23). Since
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that time with the isolation of pure populations of lymphocytes and the 
introduction of radioactive labelling techniques, it has been possible to 
study some of the biochemical events which occur in cultured lymphocytes 
and to make comparisons between normal and CLL lymphocytes.
Brody e^ al. (47) have shown in CLL lymphocytes the occurrence 
of significantly reduced amounts of radioactive carbon dioxide evolved 
from glucose and suggested that CLL lymphocytes metabolized less glucose 
through the hexose monophosphate shunt than did normal lymphocytes. These 
studies were consistent with other reports indicating decreased glucose- 
6-phosphate dehydrogenase (48) and 6-phosphogluconate dehydrogenase (49) 
activities in leukemic lymphocytes which would result in decreased sub­
strate availability for the hexose monophosphate shunt.
Stjernholm e^ (50) have reported slightly decreased utiliza­
tion of glucose in the glycolytic pathway under aerobic conditions in CLL 
lymphocytes, but the precise enzymic alteration in glucose metabolism was 
not hypothesized.
Torelli et (51) have shown that non-stimulated normal and CLL 
lymphocytes synthesized RNA primarily of a high sedimentation rate (30 to 
80 S) with very little, if any, subsequently converted to 18 S and 28 S 
ribosomal RNA.
Increased activities of di- and tripeptidases, and a reduction 
in p-glucuronidase and phosphatases (acid and alkaline) have been reported 
(52) in CLL lymphocytes. The lysosomal enzymes, the peptidases and p- 
glucuronidase,were reportedly associated with pathological and physiolo­
gical activities in cellular metabolism, but the importance of either 
increased or decreased activities was unknown. The acid and alkaline 
phosphatases were involved in the cleavage of phosphate esters, but again
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the precise significance in cellular metabolism was unknown. Therefore, 
the meaning of decreased activity in the CLL lymphocyte was unclear.
Several studies have characterized events which, occurred in nor­
mal cultured lymphocytes. Cooper et (53) found that only 1% of the non- 
stimulated lymphocytes Incorporated labelled thymidine after 72 hours in 
culture. McIntyre and Ebaugh (54) using labelled phosphate found negligi­
ble amounts of radioactivity in the DNA which was subsequently isolated. 
Thus, it was concluded that lymphocytes in vitro, in the absence of a 
mitogen, did not undergo DNA synthesis.
Weisberger et al. (55) have shown that the î . vitro uptake of 
cystine and methionine was an active process, and it has also been reported 
(56) that protein synthesis did occur in non-stimulated lymphocytes to a 
limited extent.
ENA synthesis also occurred in non-stimulated lymphocyte cultures, 
and it was of interest that about half of the 18 S ribosomal RNA was de­
graded immediately after synthesis (57). The significance of this will be 
discussed later. Cooper and Fitzgerald (58) have shown that normal lympho­
cytes produced little lactic acid under aerobic conditions. Also, Balogh 
and Cohen (59) have reported that normal lymphocytes contained ^-hydroxy- 
butyric dehydrogenase and were capable of oxidizing fatty acids to form 
acetate for use in the Kreb's cycle.
Thus, the small, circulating lymphocyte from either a normal donor 
or a CLL patient, when placed in cell culture, underwent little ENA, protein 
or carbohydrate synthesis and in the absence of a stimulant did not 
divide (60).
Morphology. Morphological studies to elucidate differences be­
tween normal and leukemic lymphocytes using supravital and Romanowsky
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stains, with phase contrast or light microscopy, have failed to show sig­
nificant differences (61). Wislocki et al. (62) in 1949 reported that 
cytoplasmic particles which stained with periodic acid-Schiff reagent were 
present in CLL lymphocytes but not in normal lymphocytes. Using these 
histochemical techniques with examination of the cells with light micros­
copy, Astaldi and Verga (63) observed that the glycogen contents of lympho­
cytes from normal donors, patients with acute lymphocytic leukemia and 
patients with CLL differed significantly. They found little or no glyco­
gen in normal and acute lymphocytic leukemic lymphocytes but greatly in­
creased amounts in the cytoplasm of CLL lymphocytes. The glycogen content 
of normal lymphocytes has been quantitated and found to be 4.1 ±0.5 mg/
10^^ cells. In CLL lymphocytes the glycogen content has been found to be
7.0 ±0.7 mg/ 10^0 cells (64).
Chromosomal studies in lymphocytes from CLL patients have not been 
as fruitful as those with chronic myelocytic leukemic cells in which an 
abnormal chromosome, the Philadelphia-1, has been found (65). Goh (66) 
reported, however, a pseudodiploid number of chromosomes in CLL lympho­
cytes, but no conclusions have been drawn from these studies.
PHA-S .imulated Lymphocytes
Biochemistry. In 1960 Nowell (67) reported that an extract of 
the red kidney bean, Phaseolus vulgaris, termed phytohemagglutinin (PHA) 
when added to cell cultures caused leukocytes to divide. Since that re­
port, it has been shown that in the presence of PHA it was the small, 
circulating lymphocyte which changed from a resting cell to a "blasto­
génie" or "transformed" cell with increased RNA, protein, carbohydrate 
and DNA synthesis followed by cell division. The temporal relationships
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of these synthetic events have been expressed within the concept of the 
"cell cycle", as discussed recently by Abell (68). The resting or non- 
stimulated cell resided in a Gap 1 phase. When a mitogen such as PHA was 
added, a specific series of changes occurred.
One of the first changes occurred within the first few minutes 
and was an increase in cyclic adenosine 3', 5*-phosphate (cyclic AMP) (69). 
There are, however, conflicting reports in the literature concerning this 
increase in cyclic AÎ1P. Novogrodsky and Katchalski (70) reported that PHA 
did not increase cyclic AMP levels nor did it stimulate adenyl cyclase in 
rat lymph node lymphocytes. In contrast, Smith et al. (71) reported 25 to 
300% increases in cyclic AMP which were observed 1 to 2 minutes after PHA 
addition. Furthermore, during the next 6 hours, there was a decrease in 
cyclic AMP, and at 24 hours it was below control (non-stimulated) values.
It is possible that the early measurements were performed in populations 
of lymphocytes different from circulating lymphocytes in their mode of 
responsiveness to PHA. Smith et (71) suggested that cyclic AMP was a 
secondary messenger of PHA activity, however, cyclic AMP addition to normal 
lymphocytes did not either increase the appearance of labelled phosphate 
into lymphocyte phospholipids or stimulate DNA synthesis, as did PHA.
Based upon the former data, Smith ^  (71) have concluded that increased
cyclic AMP was an early but not necessarily the initial change, in the 
process of lymphocyte transformation.
Within the first 10 minutes of PHA addition, Pogo et al. (72) 
have observed a marked uptake of radioactive acetate in the arginine-rich 
fractions of nuclear histones. They also suggested that this reflected 
increased histone acétylation rather than increased histone synthesis be­
cause puromycin, an inhibitor of protein synthesis, did not affect the
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Increased labelling. When tritiated uridine was added to the PHA stimu­
lated lymphocytes, it was shown that the acétylation of histones preceded 
the increased rate of nuclear RNA synthesis. These authors suggested that 
these early changes brought about alterations in DNA and histone inter­
actions which signaled later RNA synthesis initiation.
It has also been suggested that modifications in DNA and histone 
interaction could be produced by regions of high negative charge density 
resulting from the phosphorylation of proteins in the cell nucleus. It has 
been reported (73) that immediately after PHA stimulation there was an in­
crease in phosphorylation of serine and threonine residues associated with 
nuclear histones, and within 1 hour a 2-fold increase was found. This was 
also consistent with a shift from "condensed" chromatin to a more "diffuse" 
state associated with greater gene activation reflected as chromatin avail­
ability for RNA synthesis.
Fisher and Mueller (74) have shown that during the first 10 min­
utes after PHA addition, there was a 10-fold increased incorporation of 
labelled phosphate into phosphatidyl inositol, and by 30 minutes there was 
a 20-fold increase. The other 2 phospholipid fractions, 1) phosphatidyl 
choline and 2) phosphatidyl serine and phosphatidyl ethanolamine, shewed only 
0.08-fold and 0.61-fold increases in radioactive phosphate incorporation. 
This increased phosphatidyl inositol was independent of protein synthesis 
which suggested that existing enzymes were activated. These authors sug­
gested that PHA-induced activation of phosphatidyl inositol metabolism and 
thus protein transport mechanisms could bring about the removal of a gamma­
globulin from the cell. This removal would then allow the cellular genetic 
information to be expressed.
Torelli et al. (51) have reported that the RNA labelled within 1
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hour of PHA addition had a high molecular weight but within 4 hours most 
of the label was associated with ribosomal and transfer ENA of a smaller 
molecular weight. In contrast, the ENA labelled in non-stimulated lympho­
cytes was not a ribosomal ENA precursor. They suggested that this increase 
in ribosomal ENA allowed for greater translation of messenger ENA which 
was synthesized prior to stimulation. Cooper (75) has shown that prior to 
PHA-stimulation there was a marked wastage of 18 S ribosomal ENA. After 
PHA addition, this wastage was appreciably reduced, however, within 20 
minutes ribosomal ENA wastage commenced again and by 40 hours was about 
the same as non-stimulated cells. He concluded that 2 models were con­
sistent with his data, either (a) a fixed number of ribosomal ENA molecules 
must survive, or (b) a constant proportion of the ribosomal ENA molecules 
must survive. The implications of genetic control with either mechanism 
could not be clearly proposed.
Within a few hours after PHA addition, marked increases in protein 
synthesis occurred (76). In studies on glycoprotein synthesis, Hayden 
et al. (77) found that within 3 hours of PHA addition there was a doubling 
of the amount of labelled glucose into glucosamine and by the fourth day of 
culture a 10 to 20-fold increase was evident. Eighty-four percent of the 
labelled glucosamine appeared in the uridine diphosphate-N-acetylglucosamine 
pool. Incorporation into membrane fractions was found to be inhibited by 
puromycin. Proteolytic enzymes preferentially released 3 classes of glyco­
peptides from the plasma membrane fractions. These authors also noted an 
increased release of radioactivity from the cells without trypsin treatment, 
suggesting again that intracellular, soluble proteins or perhaps membrane 
autolysis was involved in early events of PHA-stimulation.
The DNA synthetic phase of the cell cycle commenced at 24 hours
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and continued for approximately a 6 hour period in which the cellular DNA 
was replicated. At the end of this 6 hour period, there was an increase 
in RNA and protein synthesis (the Gap 2 phase), followed by mitosis which 
lasted about 2 hours. Subsequently, the human peripheral blood lymphocyte 
in culture completed 2 to 4 rounds of replication.
The primary or initial event in PHA-stimulation is still unknown, 
partly because of the heterogeneity of the compound. It has been suggested 
that an interaction at the cell membrane causing either an agglutination 
of leukocytes (78), antigen to leukocyte attachement (79), precipitation 
of an alpha-globulin in the plasma (80), or an alteration of the cell mem­
brane which facilitated entry of another factor was involved (67). It 
should be noted that although many investigators have examined early changes 
in PHA-stimulated lymphocytes to ascertain what this "initiator event" 
might be, this event is still unknown.
PHA was not the only compound to cause the small, circulating 
lymphocyte to divide in cell culture, although the apparent nonspecific 
or general nature of the stimulation has been an important feature of its 
usefulness. Other agents have been found including specific antigens to 
which the cells have been pre-sensitized (81) and such nonspecific con­
ditions as cultures composed of lymphocytes from two donors (82). Recently 
inorganic and organic mercury (83), neuraminidase (84) and periodate (85) 
have been reported to initiate blastogenesis, however, the plant agglutinin 
PHA has been studied most extensively.
Although PHA had been used since 1916 (86) to hemagglutinate 
erythrocytes in the preparation of anti-hog cholera serum, and since 1949 
to separate leukocytes from erythrocytes (87), its usefulness in stimu­
lating lymphocytes to undergo events culminating in mitosis and cell division
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marked the beginning of extensive studies on the biochemistry of both 
normal and leukemic lymphocytes. PHA, a heterogeneous compound, can be 
separated into 17 components by acrylamide gel electrophoresis (88). 
Goldberg ̂  al. (89) have recently shown that the DNA-stimulating activity 
was due to neither protein, RNA, DNA nor approximately 98% of the carbo­
hydrate constituent. Rigas and Head (90) have isolated a glycoprotein of
138,000 molecular weight which was shown to be composed of subunits with 
either erythroagglutinating or lymphocyte-simulating activities.
The events following PHA-stimulation of CLL lymphocytes have not 
been studied as extensively as normal lymphocytes. Many reports in the 
literature stated that the CLL lymphocyte was a differentiated, fully 
mature cell without proliferative capabilities (91,92). However, after 
this study began, it was reported that CLL lymphocytes did respond to a 
limited extent to PHA, but the response was delayed until days 5 to 7 
after PHA addition.
Morphology. The morphological changes occurring after PHA addi­
tion have been studied in normal and CLL lymphocytes. The small, non- 
stimulated lymphocyte contained rather dense chromatin, no nucleolar 
structures, few free ribosomes and a regular double-nuclear membrane (61). 
Following stimulation with PHA, the chromatin appeared loosely packed, 
nucleolar structures were present, many ribosomes appeared in the cytoplasm 
and the nuclear membrane was irregular with large pores. Using periodic 
acid-Schiff staining, it was evident that glycogen synthesis commenced 18 
hours after PHA addition, reached a peak at 24 hours and remained constant 
up to 48 hours (93). With the exception of the periodic acid-Schiff work, 
morphological differences between the normal and CLL lymphocytes during 
blastogenesis have not been noted (94). Histochemical studies of glycogen
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in CLL lymphocytes during cell culture have not been performed.
Glycogen Metabolism 
Glycogen Regulation with Isoproterenol 
As stated earlier, a temporal relationship was found between the 
synthesis of glycogen and the onset of DNA synthesis in normal, peripheral 
blood lymphocytes in cell culture. A similar temporal relationship between 
glycogen content and DNA synthesis has been found in salivary gland cells 
of mice (95). In these studies, isoproterenol, a catecholamine, was in­
jected intraperitoneally, and there was a marked increase in the number 
of salivary gland cells. Also, after isoproterenol injection, there was 
a slight decrease in glycogen content, followed by a marked increase 
which reached a maximum shortly before the onset of DNA synthesis. 
Furthermore, these studies by Malamud and Baserga (95) showed that high 
doses of isoproterenol resulted in decreased incorporation of tritiated 
thymidine into DNA, and this decrease was correlated with decreased cellu­
lar glycogen. Malamud (96) has shown a three-fold increase in adenyl 
cyclase two to three minutes after isoproterenol injection, thus suggest­
ing a role for cyclic AMP in the catecholamine-associated activities.
Catecholamines and Cyclic AMP 
Cyclic AMP was first observed and reported by Rail and Sutherland 
(97) to be increased after the addition of epinephrine to liver homogen- 
ages. Since the report in 1958, cyclic AMP has been investigated in many 
tissues and has been found to cause either increases or decreases in many 
diverse and seemingly unrelated cellular activities. The concept of a two- 
messenger system has evolved from these studies (98). The first-messenger 
was a hormone or hormone-like substance which was released from its site of
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synthesis or storage and traveled to a "target-cell" where it Interacted 
at the membrane to bring about the adenyl cyclase-mediated conversion of 
adenosine triphosphate (ATP) to cyclic AMP which then acted as the intra­
cellular or secondary messenger. Increased cyclic AMP has been related to 
various cellular processes, in response to epinephrine, norepinephrine, 
isoproterenol, prostaglandins and theophylline additions. Several reports 
indicated that alterations in enzyme activities brought about major changes 
in many biochemical processes within the cells, such as glycogenolysis, 
lipolysis, steroidogenesis and protein synthesis (99).
Cyclic AMP and Glycogen Regulation 
In muscle and liver it has been shown that cyclic AMP regulates 
both the synthesis (100,101) and degradation (102,103) of glycogen. It 
has been known for many years that separate pathways were involved ' in the 
synthesis and degradation of glycogen, and it was recently shown (104) that 
cyclic AMP interacted with a protein kinase with enzymic specificities for 
both processes. This activated protein kinase phosphorylated the serine 
residues of phosphorylase b to convert it to the active form which then 
removed by phosphorolysis one glucose molecule at a time from the intact 
glycogen structure (105), until it reached a point approximately seven 
residues from anO|^-l,6 linkage, the branch point. At that point, amylo- 
1,6-glucosidase and transferase acted specifically to transfer the remain­
ing six glucose units and cleave the (>(̂ -1,6 -bond, thus removing the last 
glucose residue. These enzymes could completely degrade the glycogen 
structure to glucose^l-phosphate and glucose. The second function of the 
protein kinase was to convert the enzyme of glycogen synthesis, glycogen 
synthetase, to a form which was dependent upon high intracellular amounts
16
of glucose-6-phosphate for maximal activity. Glycogen synthetase trans­
ferred glucose residues from uridine diphosphoglucose forming 
bonds with the non—reducing ends of the growing glycogen molecule. Thus 
increased intracellular cyclic AMP could cause both the phosphorolysis 
of the stored glycogen and decreased synthesis, unless high concentrations 
of glucose-6-phosphate were present.
Specific Aims
This study was designed to ascertain biochemical differences be­
tween normal and CLL lymphocytes. First, however, it was necessary to ask 
if the CLL lymphocyte could be maintained in cell culture and undergo ex­
tensive amounts of DNA synthesis. Second, how could lymphocytes from CLL 
patients be characterized in terms of maximal DNA synthesis and the pro­
gression of this disease? Third, what was the mode of action of the cat­
echolamine isoproterenol in the regulation of the CLL lymphocyte? Fourth, 
since catecholamines regulate intracellular cyclic AMP in other cells, was 
this cyclic nucleotide an important regulator in CLL lymphocyte metabolism? 
Fifth, what were the characteristics of glycogen metabolism in CLL lympho­
cytes from CLL patients?
At the outset, it was anticipated that the answers to these 
questions would increase our understanding of the basic alterations in 
the leukemic process and also broaden our knowledge of the events occur­





Peripheral blood was obtained by venipuncture from fasting, 
female employees of the University of Oklahoma Medical Center, for 
studies with normal lymphocytes. For studies with CLL lymphocytes, peri­
pheral blood was obtained from CLL patients who were either untreated or 
not treated within six months prior to the study. Table 1 indicates the 
white blood cell counts and percent lymphocytes for several typical CLL 
patients, and the normal ranges for non-leukemic female donors.
Cell Culture
Lymphocytes were separated on Leukopak filters purchased from 
Fenwal Laboratories, Morton Grove, 111., or on glass wool purchased from 
Owens Corning, Corning, N. Y. Sodium heparin was purchased from the 
Upjohn Company, Kalamazoo, Mich. For isolating lymphocytes. Eagle's 
Minimum Essential Medium (MEM) was used; and for cell culture, McCoy's 
Modified 5A Medium without glutamine, antibiotics, and serum was used.
At the time of incubation, the medium was supplemented with L-glutamine 
and either autologous serum or fetal calf serum. To reduce culture con­




CORRELATION OF IN 
PERIPHERAL
VITRO DATA WITH INCREASING 
LEUKOCYTE COUNTS
WBC (10̂ /iran̂ ) Maximal DNA SynthesisDonor % Lymphocytes ■(Day) (Extent)
CLL
1 15.5 92 5 41,500
1 67.2 93 7 56,000
2 19.6 77 5 92,500
3 26.0 88 5 23,500
3 34.4 90 6 47,000
4 46.5 97 6 68,000
5 60.0 92 5 34,000
6 108.5 91 7 37,000
7 152.5 92 7 12,500
Normal
Range 7-10 20-30 3-4 37,500
(average)
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Pure Aire Corporation, Van Nuys, Calif, was used for all cell transfers 
and manipulations. Cell cultures were incubated in a National water- 
jacketed COg incubator purchased from National Appliance Co., Cherry Hill, 
N. J. All media, media supplements and trypsin solutions (0.25%) were 
purchased from Grand Island Biological Company, Grand Island, N. Y. 
Tritiated methyl-thymidine was purchased from New England Nuclear, Boston, 
Mass. Phytohemagglutinin-P, a protein extract of the red kidney bean, 
Phaseolus vulgaris, was purchased from Difco Laboratories, Detroit,
Mich.; isopropyl norepinephrine (isoproterenol) from K and K Laboratories, 
Inc., Plainview, N. Y.; cyclic AMP and AMP-5' from Sigma Chemical Co.,
St. Louis, Mo.; AMP-3' from Calbiochem, Los Angeles, Calif.; N^-2'-0- 
dibutyryl cyclic AMP from Boehringer Mannheim Corp., Mannheim, Germany; 
and theophylline from Eastman Chemicals, Rochester, N. Y.
His tochemis try
Electron microscopy was carried out by Dr. Robert E. Nordquist 
with an Hitachi HU-llB electron microscope distributed by Perkin Elmer 
Corp., Norwalk, Conn. The embedded material was sectioned with a Porter 
Blum Ultramicrotome from Ivan Sorvall, Inc., Norwalk, Conn. The cells 
were embedded in Cargille's Epoxy Resin (Araldite 6005) purchased from
Cargille Laboratories, Cedar Grove, N. J.
Light microscopy was performed with a microscope purchased 
from Carl Zeiss, Inc., New York, N. Y .
Glycogen Determinations
Phosphorylase a, imidazole buffer (grade III), B-D-glucose, 
0-dianisidine-HCl and glycogen (types III and VI) were purchased from
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Sigma Chemical Co., St. Louis, Mo.; glucose-l-phosphate, glucose-6- 
phosphate and phosphoglucomutase from Calbiochem, Los Angeles, Calif.; 
glucose-6-phosphate dehydrogenase, nicotinamide adenine dinucleotide phos­
phate (NADP) and hexokinase from Boehringer Mannheim, Corp., Mannheim, 
Germany; ATP from Schwarz Bioresearch, Inc., Orangebury, N. Y.; glucose 
oxidase (from Aspergillus niger) and peroxidase (horseradish) from Mann 
Research Laboratories, New York, N. Y.; phenol from Analar, The British 
Drug Houses, Ltd., Poole, England; and optical grade cesium chloride from 
Harshaw Chemical Co., Solon, Ohio.
Other Experimentation 
All common chemical reagents were purchased from J. T. Baker 
Chemical Co., Phillipsburg, N. J. Quantitative studies on DNA, glycogen 
and glucose and all enzymic assays were performed with a Gilford Spectro­
photometer, Gilford Instrument Laboratories, Inc., Oberlin, Ohio. Re­
fractive indices were read on an Abbe-3L-refractometer, purchased from 
Bausch and Lomb, Inc., Rochester, N. Y. Ultracentrifugation was performed 
with a Model L preparative ultracentrifuge purchased from Spinco Division, 
Beckman Instruments, Inc., Palo Alto, Calif.
Methods 
Cell Culture
Isolation and culture procedures. Human peripheral blood lympho­
cytes from both normal donors and patients with chronic lymphocytic 
leukemia (CLL) were readily obtained and easily separated from whole, venous 
blood by the procedure of Abell ejt al. (106), a modified procedure of 
Cooper and Rubin (107). One unit of heparinized (20,000 units) blood was
21
obtained by venipuncture from normal donors, aseptically dispensed into 
sterile 50 milliliter (ml) centrifuge tubes with lids and allowed to in­
cubate for one hour at 37°. The plasma supernatant which formed by gravity 
sedimentation of the erythrocytes was aseptically withdrawn and mixed with 
an equal volume of Eagle's Minimum Essential Medium (MEM), pre-warmed to 
37°. Since 20 to 30% of the leukocytes are lymphocytes, it was deemed 
necessary to separate the lymphocytes from the polymorphonuclear cells.
This was feasible because of the selective binding of polymorphonuclear 
cells to glass wool or Leukopak fibers (108).
Columns packed with one of these materials were prepared in 
advance by washing the fiber with distilled water to remove toxic materials 
and sterilizing them at 120° for 20 minutes. These sterile, fiber-packed 
columns were used to separate leukocytes from only one unit of blood. The 
plasma supernatant and MEM mixture were percolated through the fiber col­
umn at 37°. Wright stain smears of the effluent cell population indicated 
97 to 99% lymphocytes. These lymphocytes in the effluent medium were 
pelleted by centrifugation for 30 minutes at 280 x g.
Only 50 ml of venous blood were required from patients with CLL 
because of the increased peripheral leukocyte count and the increased 
lymphocyte component in the leukocyte population. Separation of lympho­
cytes from polymorphonuclear ceels on fiber columns was unnecessary due 
to the predominance of lymphocytes (85 to 99%). Immediately after veni­
puncture, therefore, the blood was placed in a sterile, heparinized 
(2,000 units) centrifuge tube and allowed to incubate for one hour at 
37°. The plasma supernatant was then removed aseptically, mixed with the 
pre-warmed MEM and centrifuged, as above, to pellet the lymphocytes.
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The lymphocytes resolved from the peripheral blood of both 
normal donors and CLL patients were counted with a standard hemacytometer 
after removal of contaminating erythrocytes by treatment with 1% acetic 
acid for one minute. The lymphocytes were appropriately diluted to a 
concentration of 10^ cells per 5 mis McCoy’s 5A Medium which was supple­
mented to 2 mM L-glutamine and 10% serum. For normal lymphocyte cultures 
autologous serum was used and was obtained by centrifuging the erythro- 
cyte-plasma component which remained in the tubes after removal of the 
leukocyte-rich plasma supernatant. The serum was aseptically withdrawn 
after centrifugation for 30 minutes at 280 x g. For CLL lymphocyte cul­
tures, fetal calf serum was added. In control experiments, it was 
shown that fetal calf serum or autologous serum could be used without 
altering either the pattern or the extent of DNA synthesis, and there­
fore the problem of obtaining sufficient quantities of autologous 
serum from such a small amount of blood from CLL patients was circumvented.
The cells and media were placed in sterile, two-ounce prescrip­
tion bottles and incubated at 37° in a humid atmosphere of 5% COg in 
balanced air.
Experimentation.
Design. The addition of 40 ug of PHA to each culture bottle con­
verted the cells from the resting to dividing state and was considered 
zero time for each experiment. As shown in Figure 1, all pretreatments 
and posttreatments of the cells were relative to this point. Figure 1 
is a schematic representation of the temporal relationships of the mani­
pulations occurring during cell culture.
Medium change. When it it was desirable to add a drug for a
EXPERIMENTAL DESIGN










■I THYMIDINE-^H INCORPORATION 
(6 HOURS)
Figure 1 - A Schematic Outline of Culture Events
24
limited period of time and remove it without significantly altering the 
cells, the following procedure was used. The cells were removed from 
the culture bottles by carefully pouring cells and media into sterile 
centrifuge tubes at the end of the drug incubation and centrifuging at 
37° for 10 minutes at 280 x g . The medium was decanted, fresh medium was 
readded quickly, and the cells were pipetted back into the warm prescrip­
tion bottles. At this point another drug or PHA could be added, and the 
cells were replaced in the incubator. Control experiments were per­
formed with each experiment to assess the effects of non-specific 
alterations on subsequent DNA synthesis, after such manipulations.
Assessment of DNA synthesis. DNA synthesis was estimated by add­
ing tritiated me thy1-thymidine (2.0 C/mm, 10 uC/10^ cells) to the cul­
tures for a 6 hour period. Radioactive determinations were performed 
with liquid scintillation spectrometer methods, and calculations gave 
specific activities, as labelled precursor incoporated per microgram 
DNA. This measurement, therefore, reflected the proliferative or DNA 
synthetic phase of the cell cycle following stimulation. Data within 
the same experiment could also be used to evaluate quantitatively diff­
erences due to manipulations, such as drug additions or other medium 
alterations.
Isolation and measurement of DNA. At the termination of the 
six hour period of tritiated methyl-thymidine incorporation, the cells 
and media were poured into chilled centrifuge tubes. The CLL lympho­
cytes, in contrast to normal lymphocytes, adhered somewhat to the glass 
bottles after PHA addition and, therefore, had to be removed with a 
trypsin solution (1 ml) which was incubated at 37° for 5 minutes. The
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chilled cells and media were centrifuged for 10 minutes at 4° at 1,000 
X g,and the supernatant was decanted. To the pellet homogenizing solu­
tion (0.4 mM potassium phosphate, pH 6.7 and 2 mM magnesium chloride)
(1 ml) was added, the pellet was resuspended and fast-frozen. Sub­
sequent procedures to remove unwanted cellular constituents and unincor­
porated radioactive material were carried out at 4°.
Briefly, the procedure was as follows: the cells were freeze-
thawed 7 times in an acetone-dry ice solution and 1.6 N perchloric acid 
(PCA) and 2.0 mg carrier-RNA were added. The cells were then chilled 
for 30 minutes. The standard centrifugation between each addition of 
solvent was 10 minutes at 1000 x g, after which the supernatant was de­
canted, the next solution added, and the resuspended pellets were disper­
sed with glass stirring rods. The sequence of solution additions in 
3 ml aliquots were 0.5 N PCA (3 times), 95% ethanol, chloroform:ethanol: 
ether (2:2:1) and acetone. The pellet obtained after the acetone treat­
ment was dryed at 57° for 30 minutes. Five-tenths ml of 0.5 N PCA was 
added, and the pellet was hydrolyzed at 90° for 30 minutes.
After hydrolysis, 0.2 ml of the hydrolysate was assayed for 
total DNA content with the diphenylamine reagent according to the method 
of Burton (109), and another 0.2 ml was added to 15 ml of Bray's solution 
(110) , for the counting of radioactivity. DNA content was based upon a 
standard calf thymus preparation. Precursor incorporation was determined 
by calculating the disintegrations per minute (DPMs) of each sample.
DPMs were calculated by dividing the counts per minute (CPMs) by the 
efficiency of the counting system. This efficiency was determined by 
adding a known amount of tritiated water to several of the samples, after
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the initial counting, thus obtaining the number of additional CPMs and 
determining the percent of the additional radioactivity recovered. All 
data shown represent the average of duplicate cultures, and each experi­
ment was performed at least twice.
Study of Glycogen
His tochemis try.
Light Microscopy. Normal and CLL lymphocytes were examined using 
several histochemical techniques to identify cellular glycogen. The cells 
were removed from cell culture medium by centrifugation, and the pelleted 
material was placed on clean microscope slides to dry. The cells were 
then stained with periodic acid-Schiff (PAS) reagent and with a hemotoxin 
counters tain (111). Briefly, the method was as follows: the dried cells 
were fixed with methanol, placed in 0.5% periodic acid for 10 to 15 minutes,
washed with distilled water, placed in the Schiff reagent until color de­
veloped, and finally rinsed with tap water. The cells were then counter­
stained by placing the slides in hemotoxin solution for 1 to 2 minutes 
and removing the excess stain with sequential rinses in tap water, acid 
alcohol (1:100, concentrated sulfuric acid: 70% ethanol), tap water, lith­
ium carbonate solution, tap water, graded ethanol solutions and finally 
in xylene.
Diastase, an ^  -amylase preparation with specificity for 
«6-1,4 glucosidic bonds, was used in control studies to show the presence 
of cellular glycogen, the mammalian polysaccharide. Glycogen was digested 
during a 2 hour pretreatment with 0.1% diastase solution in 0.02 M phosphate
buffer (pH 6.0) suspended in 0.8% sodium chloride at 37°. Following this
incubation, the cells were stained with PAS and hemotoxin.
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Electron microsqopy. Two methods were used to stain for glyco­
gen at the electron microscopic level of resolution. The first method 
utilized uranyl acetate and lead citrate (112) in the following proce­
dure. The lymphocytes were removed from the cell culture medium by 
centrifugation at 1000 x g for 10 minutes and placed in 2% glutaraldehyde 
in cacodylate buffer (0.1% sodium cacodylate, pH 7.2) for 2 hours at 4°,
centrifuged at 1000 x g for 10 minutes and placed in cacodylate buffer 
for 1 hour. The cells were centrifuged at 1000 x g for 10 minutes and 
placed in neutral buffer-formalin (10% formaldehyde in 0.03 M phosphate 
buffer) for 30 minutes, followed by treatment with a series of graded 
ethanol solutions (25, 50, 75 and 95%) for 15 minutes each, and twice in 
100% ethanol solution for 30 minutes. At room temperature, the cells 
were placed sequentially in propylene oxide, then araldite and pro­
pylene oxide solutions (25:75, 50:50 and 75:25) for 15 minutes, and then 
were left in 100% araldite overnight at 4°. The cells were embedded 
the next day at 37° for 16 to 18 hours with fresh araldite (100%), cut, 
and placed on the grids. After fixing, the cells were stained with satu­
rated uranyl acetate (in distilled water) for 15 to 60 minutes and then 
in Reynold's lead citrate for 30 to 60 minutes.
The second method used for staining cellular glycogen was the 
periodic acid-silver methenamine (PAS-M) method (113), which was as 
follows: the cells were fixed in araldite, as described above, treated
12 minutes with 2% hydrogen peroxide, rinsed with distilled water, placed 
in 1% periodic acid for 10 minutes, washed in distilled water, and then 
placed in silver methenamine (0.6% hexomethylenemine, 0.2% silver nitrate, 
2% sodium tetraborax in distilled water) for 15 minutes at 60°. The
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cells were washed 2 minutes in tap water, 1 minute in 3% sodium thio- 
sulfate and 5 minutes in tap water.
In both staining procedures, diastase control slides were 
carried along to determine the digestibility of the stained particles.
A rapid method for examining glycogen particles isolated 
during the cesium chloride centrifugation utilized a negative stain.
One drop of sample and one drop of phosphotungstic acid were placed 
together on a collodion grid and allowed to dry. When the material 
was dry, the grids were examined with the electron microscope.
Isolation. It was thought that the most suitable method for 
the isolation of glycogen from CLL lymphocytes was the cold water tech­
nique of Bueding and Orrell (114). In this procedure, all steps were per­
formed at 4°. The pelleted cells were homogenized with a tight-fitting 
glass homogenizer in 4 volumes of glycine buffer (0.2 M, pH 10.5) and 
2 volumes of water-saturated chloroform. The homogenate was centrifuged 
at 200 X g for 5 minutes, the aqueous phase carefully removed and stored 
at -20°. The lower phase and the interphase were rehomogenized with 2 
volumes of glycine buffer; centrifuged, as previously described, and 
the aspirated aqueous phase was pooled with the frozen material. This 
re-extraction procedure was repeated 4 times, and after the 5th re­
extraction the material was thawed and centrifuged at 200 x g for 5 
minutes. The resultant supernatant was centrifuged for 16 hours at 
70,000 X g in a Model L ultracentrifuge. The gelatinous pellet which was 
obtained was homogenized in glycine buffer, centrifuged at 200x g for 5 
minutes, and enough water was added to the supernatant to adjust the 
final concentration of glycogen to approximately 0.5%. The solution
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was then shaken three to five minutes with one-third its volume of chloro­
form and 1-octanol (3:1). Following centrifugation for 5 minutes at 200 x 
g, the aqueous phase was removed with the interphase, and the procedure 
was repeated with successively longer organic solvent treatments (for 1,
2, 4, and 9 hours) or until no protein interphase was evident.
Glycogen density. After isolation of glycogen from CLL lympho­
cytes by the cold water technique of Bueding and Orrell (114), the material 
was placed over cesium chloride (saturated at 0°), then centrifuged for 
3 hours at 54,000 x g in a number 40 fixed-angle rotor (115). Fractions 
were collected from the bottom of the tube by displacing 0.5 ml of the 
gradient with 0.5 ml of light paraffin oil which was added at the top of 
the tube. The density of the cesium chloride gradient formed was deter­
mined by reading the refractive index at 25° on a refractometer, and con­
verting the number obtained to density with a standard table (116). The 
phenol-sulfuric acid method was used to determine the amount of carbo­
hydrate present, and an aliquot was stained with phosphotungstic acid 
and examined with the electron microscope.
Measurement. Three different methods were selected for use in 
determining the amount of glycogen present in the cytoplasm of normal 
and CLL lymphocytes. After isolation and characterization in cesium 
chloride density gradients, the high salt concentrations present necessi­
tated the use of a non-enzymatic method. The phenol-sulfuric acid method 
was chosen due to its convenience and rapidity. The glucose oxidase 
method was useful in determining the amount of D-glucose present in 
cytoplasmic, acid-hydrolyzed homogenates, whereas glycogen quantita­
tion performed without hydrolysis of whole cell homogenates was possible
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with the phosphorylase a system due to its increased specificity and 
sensitivity.
Non-enzymic method. The phenol-sulfuric acid method (117) was 
rapid and was used to determine hexoses, di-, oligo-, and polysaccharides, 
including the methylated derivatives which possessed a free or potentially 
free reducing group. This system was advantageous when sugars could not 
be separated easily from proteins or salts. However, its major disadvan­
tage was its lack of specificity which was especially detrimental when 
nucleic acids were present. The reagent used was phenol (80%) in distilled 
water. The procedure was as follows: to the phenol reagent (0.05 ml) an
aqueous solution (2 mis) containing 10 to 70 ug of the sugar was added; the 
tube was shaken, and concentrated sulfuric acid (5 mis) was added immedi­
ately. After 30 minutes incubation at room temperature, the optical den­
sity was determined at 490 nanometers (nm) and compared with a glucose 
standard.
Glucose oxidase method. Glycogen (of-l,4,°C-l,6-linked glucose) 
when hydrolyzed yields only glucose residues. Barton (118) described a 
method for measuring D-glucose by utilizing glucose oxidase (E.G. 1.1.3.
4), horseradish peroxidase (E.G. 1.11.1.7) and 0-dianisidine (DH^), as a 
hydrogen donor. The reaction was as follows:
D-glucose gluconic acid+   > +
glucose oxidase-FAD glucose oxidase-FADHg
glucose oxidase-FADHg + 0 ^ --------------->  glucose oxidase-FAD +
^2°2 ° ^ 2 ------------------------------- >  + D
Glucose oxidase had major specificity for p-D-glucose with only
minimal activity toward 2-deoxy-D-glucose, mannose, xylose and galactose 
and therefore provided a rather sensitive method for the measurement of
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glucose in the presence of the common cellular sugars. Glucose oxidase, 
isolated from Aspergillus niger, contained two FAD molecules per molecule 
of enzyme and catalyzed the oxidation of p-D-glucose to gluconic acid and 
hydrogen peroxide when the system was well aerated (119). It had been re­
ported (120) that hydrogen peroxide inactivated reduced glucose oxidase at 
acidic pH by oxidizing the methionine residues to methionine sulfoxide. 
Horseradish peroxidase circumvented this inactivation of glucose oxidase 
by converting the hydrogen peroxide to water, and 0-dianisidine functioned 
as a hydrogen donor in the reaction.
A modified method of Black and Anglin (121) was adopted because 
of the limited number of lymphocytes available, and the greater require­
ment for sensitivity. The major changes included incubation at pH 7.1, 
to decrease maltase activity, and extension of incubation time to 60 min­
utes. The reaction mixture contained horseradish peroxidase (0.135 mg), 
0-dianisidine (0.135 mg)and glucose oxidase (0.135 mg) in phosphate buffer 
(0.5 M, pH 7.1). The sample (0.2 ml) and reaction mixture (2.7 mis) were 
incubated at 37° for 60 minutes. The reaction was stopped with hydro­
chloric acid (1.3 mis, 2 N), and the optical density determined at 450 nm.
Cells were prepared as follows: lymphocytes were removed from the
medium by centrifugation at 1,000 x g for 5 minutes at 4°. Because the 
medium contained three grams of glucose per liter, the cells were rinsed 
three times in an isotonic solution, pelleted by centrifugation, as des­
cribed above, and the supernatants were assayed for glucose and for any 
cellular glycogen which might have been leached from the cells during the 
rinses. The cells were then homogenized and hydrolyzed at 100° for 30 min­
utes in hydrochloric acid (2.5 N), centrifuged at 1,000 x g for 5 minutes
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at 4°, and the supernatant pH neutralized with sodium hydroxide.
Phosphorylase and hexokinase method. Passonneau et al. (122) 
described an enzymatic method which was useful in measuring as little as
0.5 microgram of glycogen spectrophotometrically in the presence of all 
cellular structures. The specificity of phosphorylase a (E.G. 2.4.1.1), 
phosphoglucomutase (E.G. 2.7.5.1) and glucose-6-phosphate dehydrogenase 
(E.G. 1.1.1.49) provided a system to measure the breakdown of glycogen to 
glucose-l-phosphate. The product of the amylo-l,6-glucosidase cleavage 
at the 1,6 branch points, glucose, was measured in a second system with 
hexokinase (E.G. 2.7.1.1). A schematic representation of the entire 
reaction is shown below:
4 5Glycogen--------- > glucose--------- ;
'1 2 3'— >  glucose-l-phosphate— ^ glucose-6-phosphate~-)^6-P-gluconolactone
NADP"*" '^NADPH + h"*"
Enzymes: 1. phosphorylase a; 2. phosphoglucomutase; 3. glucose-6-
phosphate dehydrogenase; 4. amylo-l,6-glucosidase; and 
5. hexokinase.
The incubation mixture consisted of imidazole buffer (0.05 M, 
pH 7.0) containing magnesium acetate (0.5 mM), NADP"*" (1 mM), AMP-5' (0.1 iriM), 
KgHPO^ (5 mM), (ethylenedinitrilo)tetraacetic acid (1 mM), bovine plasma 
albumin (0.02%), activated phosphorylase a (10 ug), phosphoglucomutase 
(10 ug) and glucose-6-phosphate dehydrogenase (10 ug). The second system 
consisted of ATP (1 mM), magnesium chloride (1 mM) and hexokinase (10 ug) 
which was added to the phosphorylase system, after the complete degradation 
of glycogen to glucose-l-phosphate and glucose. The glycogen which was 
degraded to glucose in the second system was measured and found to be 9%
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of the total glucose present in the standard glycogen preparation.
Control experiments indicated that the commercially prepared 
glycogen contained no phosphorylase a, glucose-6-phosphate dehydrogenase, 





The first studies were designed to ascertain the culture condi­
tions necessary for maximal cellular proliferation to occur. In this 
experimental system, DNA synthesis was assessed and was reflective of 
the stability and proliferative capabilities of the lymphocytes in cul­
ture. The schematic representation of culture events is shown in Figure
1. In Figure 2, the mitogen PHA was added to the normal lymphocyte 
cultures to determine the concentration required for maximal DNA syn­
thetic activity. An aqueous solution of PHA was added to the culture 
bottles at time zero at concentrations from 3 to 600 ug per culture 
bottle, and DNA synthesis and DNA content were determined at day 3.
The non-stimulated control cultures, without PHA, contained 15 ug DNA 
per culture at this time compared with the PHA-stimulated cultures which 
contained 28 to 32 ug DNA per culture when 30 to 60 ug PHA were added. 
This two-fold increase in DNA content, indicative of a doubling of cells, 
along with the occurrence of maximal DNA synthetic activity indicated 
that 30 to 60 ug of PHA was optimal for these cultures. Other labora­
tories had reported that PHA was cytotoxic at higher concentrations (123), 
and our results confirmed those findings.

















Figure 2 - PHA Concentration Range for Maximal DNA Synthesis in Normal 
Lymphocyte Cultures.
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optimal concentration of cells, a typical PHA-response curve, as shown in 
Figure 3, was obtained. In this study, normal lymphocytes were cultured 
in the presence of 40 ug of PHA., and DNA synthesis was found to begin 
between days 1 and 2 with maximal synthesis occurring at day 3 or 4. In 
most experiments, however, by day 6 DNA synthesis was only approximately 
10% of the maximal amount observed at day 3.
Earlier reports indicated that CLL lymphocytes were immunolo- 
gically defective and when placed in cell culture were either unable to 
divide (124) or did so to a limited extent and at a delayed time (125,126). 
This investigation indicated, however, that CLL lymphocytes did synthesize 
DNA to an extent comparable to normal lymphocytes, and the time of the 
maximal response was delayed. Maximal DNA synthesis occurred 5 to 7 days 
after PHA addition which was 1 to 4 days later than the maximal response 
of normal lymphocytes. It was found in these studies that patients could 
be arbitrarily grouped according to the progression of the disease and the 
day of maximal DNA synthesis. As shown in Figure 4, maximal DNA synthesis 
in a patient with a relatively low peripheral leukocyte count or white
3blood cell count (WBC) of less than 30,000/ mm occurred at day 5. In
3contrast, a patient with a WBC count of 30,000 to 100,000/ mm exhibited 
maximal DNA synthesis at day 6, as shown in Figure 5, and a patient with
3a WBC count of greater than 100,000/ mm demonstrated maximal DNA synthesis 
at day 7, as shown in Figure 6.
The correlation between the WBC count and the day of maximal DNA 
synthesis has been found in almost all of the more than 30 CLL patients 
which have been studied in our laboratory (106). Two patients were followed 














Figure 3 - DNA Synthesis Estimated in a Normal Lymphocyte 








Figure 4 - DNA Synthesis Estimated following PHA Stimulation 










Figure 5 - DNA Synthesis Estimated following PHA Stimulation 
of Lymphocytes from a CLL Patient with a Medium Peripheral Leukocyte 
Count
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Figure 6 - DNA Synthesis Estimated following PHA Stimulation 
of Lymphocytes from a CLL Patient with a High Peripheral Leukocyte 
Count
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correlated with a subsequent delay in the time of maximal DNA synthesis. 
Table 1 indicates the WBC count, the percent lymphocytes, the day of maxi­
mal DNA synthesis and the extent of DNA synthesis for each of the seven 
typical CLL patients listed. Also, in these studies none of the CLL lympho­
cyte cultures was unresponsive to PHA additions.
The PEA requirements for cultured normal and CLL lymphocytes are 
shown in Tables 2 and 3. In the experiments described in Table 2, the 
mitogen PHA was added to the lymphocyte cultures at time zero, and after 
24 hours the medium was changed. In the control cultures, PHA was immedi­
ately readded (40 ug/culture), and the specific activities thus obtained 
were expressed at 100% activity. In other cultures, PHA was either not 
readded or readded at days 2, 3 or 4 for the CLL cultures and at day 2 
for the normal lymphocyte cultures. The results indicated that if PHA 
was not readded 46 to 51% of the control activity was found in either the 
CLL or normal cultures at day 3. In contrast, at days 5 to 7 in the CLL 
lymphocyte cultures only 12 to 15% activity was observed, and in normal 
lymphocyte cultures 37 to 64% of the control values were obtained at days 
4 and 5, respectively. The readdition of PHA to CLL cultures was followed 
by a marked increase in DNA synthesis, while the readdition of PHA to nor­
mal cultures had only slight effects when compared with control values.
In the studies with CLL lymphocytes, it was apparent that the 
initiation of proliferative events began between 48 and 72 hours after PHA 
addition, rather than within a few minutes of mitogen addition, as was 
evident in normal cultures, and CLL lymphocytes required greater amounts of 
PHA than normals. A second feature of the CLL lymphocyte culture was that 
when PHA was readded at either day 2 or 3, maximal DNA synthesis was de­
layed until day 6, and this synthesis was increased 2.6 to 3.2-fold.
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TABLE 2
PHA REQUIREMENT OF CLL LYMPHOCYTES
Conditions Day in Culture 
3 5 6 7
Control:
Media change at day 1 
Readd PHA immediately 
(% of control)® 100 100 100 100
Experimental:
(% of control)
No PHA readded 51 12 15 13
Readd PHA at day 2 100 155 263 181
Readd PHA at day 3 46 321 197
Readd PHA at day 4 19 136 207
PHA REQUIREMENT OF NORMAL LYMPHOCYTES
Conditions Day in Culture 
3 4 5
Control:
Media change at day 1 
Readd PHA immediately 
(% of control) 100 100 100
Experimental:
(% of control)
No PHA readded 46 37 64
Readd PHA at day 2 44 43 151
Control Specific Activities (DPMs/ ug DNA)
CLL lymphocytes : day 3 (4,615), day 5 (48,807), day 6 (41,199)
, day 7 (37,744).
Normal lymphocytes: day 3 (30,842), day 4 (15,099), day 5 (2,787)
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TABLE 3
PHA REQUIREMENT OF CLL LYMPHOCYTES
Conditions: Day in Culture:
5 6 7
Control:
Media change at day 3 
Readd PHA immediately 




No PHA readded 71 65 53
Readd PHA at day 5 107 115
Control Specific Activities (DPMs/ ug DNA)
CLL lymphocytes: day 5 (43,559), day 6 (61,385), day 7 (45,883).
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Although there was a 1.5-fold stimulation of DNA synthesis at day 5 in 
the normal lymphocyte cultures, the day of maximal synthesis was still 
day 3.
Table 3 shows the PHA requirements of CLL lymphocyte cultures
following medium change at day 3, with and without the readdition of PHA
to the cultures. When PHA was not readded, it was evident that the DNA
synthesis observed at days 5 to 7 differed significantly from the synthesis
observed after media change at day 1, without PHA readdition. Therefore,
50 to 70% of the potential DNA synthetic activity had already been 
initiated, and readdition of PHA at day 5 increased this to the control 
values. This strongly suggested that PHA was required in the medium at 
specific times in order to initiate events culminating in DNA synthesis 
and cellular division.
Table 4 shows the changes in maximal DNA synthesis noted when 
CLL lymphocytes were preincubated 24, 48 and 72 hours before PHA was 
added to the medium. Preincubation for 24 or 48 hours did not signifi­
cantly alter the amount of DNA synthesis noted at days 1 through 5 in 
cell culture, with a 48 hour incubation, however, synthesis was slightly 
increased at day 7. In contrast, when the cells were preincubated for 
72 hours, there was a 2-fold increase in DNA synthesis at day 5, although 
the time of maximal synthesis was not altered.
Marked alterations in both the extent and time of maximal DNA 
synthesis were observed when the CLL lymphocytes were pretreated for 24 
hours with the catecholamine isoproterenol (2 x 10  ̂M) before the addi­
tion of PHA, as shown in Figure 7. In this experiment there was a 
marked reduction in maximal DNA synthesis which occurred at day 4, when 
DNA synthesis was maximal in some normal lymphocyte cultures. When
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TABLE 4
EFFECT OF PREINCUBATION ON SUBSEQUENT DNA 
SYNTHESIS IN CLL LYMPHOCYTE CULTURES




(% of control)^ 100 100
Experimental:
(% of control)
24 hour preincubation 132 100
48 hour preincubation 100
72 hour preincubation 41 204
Control Specific Activities (DPMs/ ug DNA)














Figure 7 - DNA Synthesis Occurring in a CLL Lymphocyte Culture after 24 Hour 
Preincubation with and without Isoproterenol
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normal lymphocytes were treated with the same concentration of isopro­
terenol, no inhibition of DNA synthesis was noted (106).
Figure 8 shows a CLL lymphocyte culture in which isoproterenol 
(1.6 X 10 M) was added either before or after the addition of PHA.
Curve A represents the PHA-stimulated control cultures, without drug addi­
tion, with maximal synthesis observed at day 5. Curve B shows the results 
of 24 hour pretreatment with isoproterenol, followed by the addition of 
PHA at time zero. Maximal DNA synthesis was still seen at day 5, but 
synthesis was inhibited 70% . Likewise, extensive inhibition was obtained 
when isoproterenol was added after PHA (curves C, D, E and F). Iso­
proterenol addition 20 minutes after PHA (curve C) effectively inhibited 
any further DNA synthesis (99%) , whereas isoproterenol addition at day 
1 (curve D) had little effect on the synthesis observed at day 2, but 
subsequent synthesis was completely inhibited. When isoproterenol was 
added at day 2, (curve E), the DNA synthesis at day 3 was similar to the 
day 2 control. At later days, however, a decrease in synthesis was noted. 
The addition of isoproterenol at day 3 (curve F) was followed by an 
increase in synthesis at day 4, and a decrease was again found at later 
times, and this decrease observed was parallel with the decreased DNA 
synthesis of control cultures.
Figure 9 shows the pattern of inhibition of isoproterenol in 
CLL cultures over a 100-fold concentration range. In these studies, maxi­
mal DNA synthesis was observed 7 to 8 days after PHA addition to the
cultures at time zero. Isoproterenol was added to the cultures 20 minutes 
-5 -3after PHA at 10 to 10 M concentrations. Curve A reflects the DNA













Figure 8 - Isoproterenol Treatment of CLL Lymphocytes







Figure 9 - DNA Synthesis in CLL Lymphocyte Cultures with 
and without Isoproterenol Additions at 10“  ̂to 10“^ M Concen­
trations after PHA Stimulation
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Isoproterenol and curve C 10 ^ M Isoproterenol additions. At culture 
day 7, DNA synthesis was inhibited 70, 99 and 100% at 10~^ M, lO”  ̂M and
-310 M, respectively.
Since there were many reports in the literature (127,128) which 
indicated that catecholamines in general and isoproterenol in particular 
inhibited various cellular processes by effecting intracellular increases 
in cyclic AMP, it was important to ascertain the effects of this cyclic 
nucleotide on DNA synthesis in PHA-stimulated lymphocytes. Figure 10 
shows the results of cyclic AMP additions of 10  ̂M to 10  ̂M, curves A to 
C, to CLL lymphocytes at 20 minutes after PHA addition. Although the ob­
served inhibition of DNA synthesis was not as great as that observed with 
isoproterenol, the effects were dose-dependent at day 7 with 12, 48 and 
72% inhibition at 10  ̂M, 10 ^ M and 10  ̂M, respectively. This was not 
unexpected, due to the reports in the literature (128) which suggested 
that the dibutyryl derivative of cyclic AMP was more effective in bringing 
about cellular alterations than cyclic AMP.
The results obtained following dibutyryl cyclic AMP addition are
shown in Figure 11. As stated previously, the additions were made at 20
-5 -3minutes after PHA at 10 M to 10 M, curves A to C, and at day 7, the in­
hibition observed was dose-dependent and found to be 65, 91 and 99% for 
10  ̂M, 10  ̂M and 10  ̂M, respectively.
Figure 12 illustrates that dibutyryl cyclic AMP and isoproterenol 
produced essentially the same inhibition of DNA synthesis, expressed as per­
cent inhibition, over the entire 100-fold concentration range, 10  ̂to 10  ̂
M, therefore, strongly suggesting that isoproterenol and dibutyryl cyclic 
AMP were producing similar changes within the CLL lymphocytes.







Figure 10 - DNA Synthesis in CLL Lymphocyte Cultures with







Figure 11 - DNA Synthesis in CLL Lymphocyte Cultures with 
and without Dibutyryl Cyclic AMP Additions at 10“^ to 10"^ M 
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Figure 12 - The Percent Inhibition of DNA Synthesis in CLL 
Lymphocyte Cultures after Dibutyryl Cyclic AMP and Isoproterenol 
Additions
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tested. Additions of AMP-3* produced slight inhibition at 10~^ M and 
50% inhibition of DNA synthesis at high concentrations (10~^ M). The 
addition of AMP-5* also caused 50% inhibition at high concentrations (10~^
M) , but neither monocucleotide produced dose-dependent effects.
Isoproterenol and dibutyryl cyclic AMP produced dose-dependent 
inhibition and at 10 ^ M essentially inhibited DNA synthesis completely. 
Therefore, it was highly probable that AMP-3* and AMP-5* at high concen­
trations were involved in nonspecific reactions which were independent of 
adenyl cyclase—mediated activity. Another control experiment showed that 
each of these adenosine mononucleotide additions did not change the pH of 
the medium more than 0.1 pH unit, and therefore this inhibition of DNA syn­
thesis could not have been due to cellular alterations effected by extreme 
pH shifts.
Part of the enhanced effectiveness of dibutyryl cyclic AMP was its 
insensitivity to cleavage by phosphodiesterase (129) to the less active 
AMP-5* with concurrent loss of cyclic-AMP mediated effectiveness. It was 
suggested that the methyl xanthine theophylline inhibited this cleavage 
and thereby potentiated or mimicked the effect observed after isoproterenol 
addition by either increasing or sustaining the levels of intracellular 
cyclic AMP. Figure 13 illustrates the results obtained after isoproterenol 
(4 X 10  ̂M) and theophylline (2 x 10 ^ M) were added to the cultured CLL 
lymphocytes either 24 hours before or at various times after PHA-stimulation. 
The results, expressed as percent inhibition of DNA synthesis, indicate that 
the greatest effect occurred when the drugs were added after PHA either at 
20 minutes (curve B) or 24 hours (curve C). When the drugs were added 24 
hours before PHA (curve A), 91% inhibition occurred at day 5, and with drug 











Figure 13 - The Percent Inhibition of DNA Synthesis in CLL 
Lymphocyte Cultures after the Addition of Both Isoproterenol and 
Theophylline Either before or after PHA Simulation
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As shown in Table 5, the addition of theophylline (2 x 10“  ̂M) , 
alone, had no effect on the cultures of CLL lymphocytes either 24 hours 
before or 20 minutes after PHA addition. Isoproterenol (4 x 10“  ̂M) addi­
tion resulted in 45 to 55% inhibition. In contrast, when isoproterenol 
and theophylline were added to the cultures at the same time, 91 and 99% 
inhibition was observed. These studies, therefore strongly suggested that 
theophylline was potentiating the intracellular effectiveness of isopro­
terenol in the CLL lymphocyte.
In other experiments additions of theophylline at concentrations 
from 10  ̂M to 2 X 10  ̂M to normal and CLL lymphocytes at 20 minutes
after PHA resulted in no significant changes in either the expected time
-5or extent of DNA synthesis. The additions of isoproterenol at 4 x 10 M,
-4theophylline at 2 x 10 M, or both compounds to PHA-stimulated normal
lymphocyte cultures resulted in no inhibition of DNA synthesis. Further-
—4more, neither cyclic AMP nor dibutyryl cyclic AMP at 10 M concentration 
demonstrated any significant effect on DNA synthesis in normal lymphocytes.
There were several reports in the literature concerning the stimu­
lation of human lymphocytes with various agents, including cyclic AMP 
(69), and trypsin solution (130). As shown in Table 6, preliminary 
experiments with normal, non-stimulated lymphocytes indicated that cyclic
_Q —12AMP at concentrations of 10 to 10 M did not stimulate the cells to
undergo DNA synthesis. Also, theophylline at 10~^ M neither mimicked
nor potentiated any cyclic AMP activity. Trypsin incubation (0.25%) for 
o10 minutes at 37 was without effect on normal lymphocyte cultures when 
PHA was not present.
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TABLE 5
EFFECTS OF THEOPHYLLINE AND ISOPROTERENOL ON 
DNA SYNTHESIS
Time of Addition Additions Specific Activity 
(DPM/ug DNA)
% Inhibition












EFFECTS OF CYCLIC AMP, DIBUTYRYL CYCLIC AMP, THEOPHYLLINE 
AND TRYPSIN ON NON-STIMULATED,
NORMAL LYMPHOCYTES
Agent % of Control DNA Synthesis Concentration
Cyclic AMP 0.1 10"12 M
0.1 10"^° M
0.1 10"® M
Dibutyryl Cyclic AMP 0.2 10“® M
Theophylline 0.1 —6 10 M
Trypsin 0.1 (0.25%)
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Characterization of Glycogen 
The previous studies have shown that the CLL lymphocyte was uni­
quely sensitive to both Isoproterenol and dibutyryl cyclic AMP, and, there­
fore, further experimentation was undertaken to elucidate the cellular 
mechanism which brought about these changes after drug additions. Earlier 
studies (62) had clearly shown that CLL lymphocytes contained large amounts 
of stored glycogen, and therefore one possible role for cyclic AMP In the 
CLL lymphocyte was the phosphorolysls of glycogen to glucose-l-phosphate 
which had been reported to occur In muscle and liver (102,103).
Figure 14 Is an electron micrograph of a normal lymphocyte, typi­
cal of the many cells examined. In contrast to the ultrastructure observed 
for the normal lymphocyte, the CLL lymphocyte contained a globular parti­
cle In the cytoplasm, as shown In Figure 15. This particle was Identified 
as glycogen on the basis of digestion with diastase and stain retention with 
periodic acld-sllver methenamlne. The membrane-bound particle of glycogen 
varied In size from 0.2 to 0.5 microns which corresponded In size with the 
periodic acld-Schlff positive material observed with light microscopy.
Most of the particles were round suggesting a spherical shape, and one or 
two were found In each CLL lymphocyte. The Inset, of Figure 15, shows a 
higher magnification of the particle (xl20,000). In size and appearance 
this particle of glycogen was unlike the classical beta (Individual) or 
alpha (aggregated) particles which have been observed In liver and other 
tissues (112), therefore suggesting that the stored glycogen In the CLL 
lymphocyte had either an unusual structure or had been packaged within 
the cell In a rather unique form.
A second method used to characterize the ultrastructure of the CLL 
lymphocyte glycogen was the periodic acld-sllver methenamlne, as shown
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Figure 14 - An Electron Micrograph of a Normal Peripheral
Blood Lymphocyte (Magnification: x38,0G0)
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Figure 15 - An Electron Micrograph of a CLL Peripheral
Blood Lymphocyte (Magnification: x35,Q00), with Higher Magni­
fication (xl20,000) of the Glycogen Particle as Inset
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Figure 16 - An Electron Micrograph of a CLL Peripheral
Blood Lymphocyte Stained with Periodic Acid-Silver Methenamlne
(Magnification: x240,000)
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in Figure 16. Once again the particle of cytoplasmic glycogen was observed, 
and, although not shown here, was identified by digestion with diastase.
Examination of periodic acid-Schiff (PAS) stained cells under 
the light microscope also indicated the presence of large amounts of 
glycogen in CLL lymphocytes, as shown in Figure 17. These brightly- 
stained red particles were abundant in the cytoplasm of the non-stimulated 
CLL lymphocyte, and approximately 10-fold greater amounts of stored glyco­
gen were observed in the CLL lymphocyte than in normal lymphocytes. This 
PAS-stained material was comparable in size to the particles of glycogen 
observed with the electron microscopy, and the ability to stain with PAS 
was completely abolished with diastase treatment.
Preliminary studies with PAS staining of PHA-stimulated CLL lympho­
cytes, during the course of cell culture, have shown that the addition of 
isoproterenol to the cells was followed by the complete loss of stored gly­
cogen within 24 hours, as shown in Figure 18. PHA-stimulated control cul­
tures, without the addition of isoproterenol, did not show this specific 
loss of glycogen.
Having visualized the intact glycogen particles at the electron 
microscopic and light microscopic levels, the next step involved the isola­
tion of the cytoplasmic material to unequivocally identify it as glycogen. 
The material, extracted by the cold-water technique, was insoluble in cold 
ethanol and was resistant to ribonuclease, deoxyribonuclease and pronase 
treatments but was degraded by ©(.-amylase.
The isolated glycogen banded in a cesium chloride gradient with 
the major component at a density of 1.64, as shown in Figure 19. As re­
ported for rat liver (115), a minor component of membrane-bound glycogen 
banded at 1.33 (g/cc). A sample from the 1.64 peak was removed for
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Figure 17 - A Light Photomicrograph of CLL Lymphocytes 
Stained with Periodic Acld-Schlff Containing Large Glycogen 
Particles
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Figure 18 - A Light Photomicrograph of a CLL Lymphocyte 












Figure 19 - Glycogen Isolated from CLL Lymphocytes Banded in a Cesium Chloride 
Density Gradient at 1.64 and 1.33
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negative staining with phosphotungstic acid. Figure 20 is an electron 
micrograph of the isolated glycogen particles. The particles were found 
to range from 50 to 57 millimicrons in size which corresponded with the 
upper theoretical limits of B-particle size, as shown in Table 7 (115).
Preliminary studies were undertaken to correlate the pattern of 
DNA synthesis with the pattern of glycogen synthesis in both the normal 
and CLL lymphocyte. Figure 21 illustrates that DNA synthesis in normal 
lymphocytes commenced about 24 hours after PHA addition and reached a maxi­
mum at day 4. In the same experiment, glycogen synthesis commenced shortly 
after the addition of PHA and reached a maximum at day 2. The amount of 
glycogen remained approximately constant until day 3 and thereafter de­
clined slowly.
Figure 22 shows the relationship of glycogen synthesis to DNA 
synthesis in lymphocytes from a CLL patient. In this culture, maximal DNA 
synthesis occurred at day 5. In contrast to the normal lymphocytes, the 
amount of glycogen present at zero time of culture gradually decreased 
during the first 2 days of culture, but glycogen was later resynthesized. 
This 2-fold increase, compared to the initial amounts of glycogen, was 
comparable to the increase noted in normal lymphocytes. From days 3 to 5, 
the amount of glycogen remained relatively constant, during the time of 
maximal DNA synthesis, and dropped significantly in a manner parallel 
with the decreased DNA synthesis.
The glycogen contents of freshly isolated lymphocytes from two 
normal donors and two patients with CLL were also determined using either 
glucose oxidase or phosphorylase a assays. In lymphocytes from normal 
donors the glycogen concentration was found to be 0.060 ug/ ug DNA and 
0.130 ug/ ug DNA, and in CLL lymphocytes the glycogen content was found to
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Figure 20 - An Electron Micrograph of the Glycogen Particles 






Alpha ) <200 <2000
Beta ) 15-55 150-550
Gamma ( k ) 2.5-3.5 25-35
from Barber, A. A., Harris,W. W. and Anderson, N. G. 1966 
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Figure 21 - Glycogen Content and DNA Synthesis Assessed in 
a Normal Lymphocyte Culture after PHA Addition with Glucose 
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Figure 22 - Glycogen Content and DNA Synthesis Assessed 
in a CLL Lymphocyte Culture after PHA Stimulation with Phos­
phorylase a Measurement of Glycogen
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3be 0.209 ug/ ug DNA in a patient with a low WBC count of 25,000/ mm and
q0.475 ug/ ug DNA in a patient with a WBC count of 77,100/ mm .
Because of the contamination of cultured lymphocytes with ery­
throcytes (RBCs) and therefore a possible effect on the glucose oxidase 
assay, it was necessary to assess any possible effects, both positive and 
negative. It was conceivable that RBCs could contribute to the glycogen 
determinations by providing either glucose from the membranes or heme- 
containing compounds and reduce the values by interference with either 
uric acid (131) or lysosomal enzymes released after cell death (132). 
Consequently, normal blood (0.02 ml) was removed from culture and assayed 
with and without exogenously provided glycogen (type III) at the culture 
days listed (Table 8). All samples except the last one were hydrolyzed 
for 30 minutes at 100°. From this study, it was evident that even great 
numbers of RBCs did not contribute significantly to the total glucose 
determinations. RBCs per se contributed slightly positive effects at 
zero time and slightly reduced the values at later times in cell culture.
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TABLE 8
EFFECTS OF ERYTHROCYTE CONTAMINATION 
ON GLUCOSE OXIDASE ASSAY
Sample Day Addition ug Glycogen
1 0 RBC 6; —  —
2 0 RBC + 25 ug Glycogen 27; 28
3 1 RBC 5; 8
4 1 RBC + 25 ug Glycogen 22; 22
5 3 RBC 4; 5
6 3 RBC + 25 ug Glycogen 24; 23
7 4 RBC 7; 4
8 4 RBC + 25 ug Glycogen 22; 24
9 7 RBC 3; ----
10 7 RBC + 25 ug Glycogen 21; -
11 8 RBC . 4; 4
12 8 RBC + 25 ug Glycogen 20; 21
13 1 RBC + 25 ug Glycogen 28; ----
CHAPTER IV
DISCUSSION
Several reports in the literature have correlated the PHA-respon- 
siveness of CLL lymphocytes, observed as blastogenesis or transformation, 
and the immunocompetency of the leukemic patient (124). Similarly, other 
studies have shown that lymphocytes from patients with Down's syndrome 
(133) responded to PHA very poorly, and the authors suggested an impairment 
of immune functions. The studies presented here, however, have indicated 
that CLL lymphocytes did respond to PHA and exhibited levels of maximal 
DN4 synthesis which were comparable to those observed in normal lymphocytes, 
although the response was delayed. Possibly, the reduced response observed 
in the earlier studies with CLL lymphocytes was due to either a nutrition­
ally inadequate medium or non-ideal cell concentrations.
In considering the first possibility, it was noted in a study (125) 
that tissue culture medium 199 was used, and in another study (126) Eagle's 
basal medium was used. Modified McCoy's 5A medium was used in our study, 
and the major differences between these two media and Modified McCoy's 5A 
medium were the presence of Bacto-peptone (600 mg/liter), asparagine (45 mg/ 
liter) and cysteine (31.5 mg/liter) which were present in Modified McCoy's 
5A medium. From these differences, it was apparent that the leukemic cells 
required greater amounts of free nitrogen or amino acids than normal lympho­
cytes for the events of blastogenesis and cell maintenance.
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A second possibility for the differing results was the cell 
concentrations used in lymphocyte cultures. In one study (125), the cells 
were cultured at 10^ per ml medium, in another study (126) at 5 x 10^ per 
ml medium, and in our studies at 2 x 10^ per ml medium (106). From pre­
vious experiments (106) it has been ascertained that these higher concen­
trations of cells were required in order to observe maximal DNA synthesis. 
It is possible that for CLL lymphocytes in culture this higher concentra­
tion is necessary for the cells to establish optimal cell contact in order 
to initiate or continue the events required for cell division. In support 
of this concept, it is of interest to note that membrane alterations have 
been found in virus-transformed cells (134). These altered growth charac­
teristics were reversed when the cells were treated with peptide fragments 
of concanavalin A (135), a compound which probably altered the membrane 
configuration.
The studies presented here demonstrated that by utilizing the 
optimal culture conditions CLL lymphocytes responded to the mitogen PHA 
to an extent comparable with normal lymphocytes, but the time of maximal 
synthesis was delayed. Normal lymphocytes demonstrated maximal DNA syn­
thesis at day 3 or 4, whereas CLL lymphocytes demonstrated maximal DNA 
synthesis 1 to 4 days later. Lymphocytes from CLL patients with relatively 
low, medium and high WBC counts demonstrated maximal DNA synthesis at days 
5, 6 and 7, respectively. It was also of interest to note that our studies 
showed that the delay in DNA synthesis with the progression of the disease 
was also correlated with increased glycogen content. These findings were 
consistent with Vereschagina's studies on glycogen content in CLL (136).
Although CLL lymphocyte cultures demonstrated maximal DNA synthe­
sis 5 to 7 days after PHA addition to the culture, there was some DNA
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synthesis occurring at days 3 and 4. This moderate amount of DNA synthesis 
occurred at a time when lymphocytes from normal donors demonstrated maxi­
mal DNA synthesis, and therefore suggested that two or more populations of 
cells existed in the peripheral blood of patients with CLL. Theoretically 
there are at least two possible approaches, physical and biochemical, for 
differentiating potentially different lymphocyte populations. Recently, 
Sykes et al. (137) reported that Ficoll gradients could be used to separate 
cell types which were of different densities, but such differences are not 
known to exist between normal and CLL lymphocytes. Therefore, in this 
study, methods were employed for distinguishing the "leukemic" component 
of the CLL cultures using manipulations such as media changes and drug 
additions. From the results of these studies, it was apparent that the DNA 
synthesis observed at day 3, in CLL cultures, represented a more normal­
like component of lymphocytes which coexisted with the "leukemic" lympho­
cytes in the peripheral leukocyte population of the CLL patient. Two 
lines of experimental evidence supported this hypothesis.
First, the patterns of DNA synthesis were different in normal and 
CLL lymphocyte cultures after medium changes both with and without the re­
addition of PHA. Previously published papers were quite confusing in their 
characterizations of the PHA requirements of normal lymphocytes. Cooper 
and Rubin (138) stated that PHA was required continuously in culture in 
order to observe the increased synthesis of nonribosomal RNA. Furthermore, 
if PHA was removed by washing, the RNA synthetic pattern changed back to 
the 45 to 50 S species which were synthesized prior to PHA addition. Pol- 
gar e^ al. (139) published that the events leading to the formation of the 
blastoid cell were identical in cultures continuously exposed to PHA and 
those exposed to PHA for only 24 hours. At days 8 to 12 in cultures
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exposed to PHA for only 24 hours, however, DNA synthesis was significantly 
reduced in comparison to those normal lymphocyte cultures in which PHA was 
continuously present. Experiments undertaken in this laboratory to deter­
mine the PHA requirements for normal lymphocyte cultures demonstrated that 
when PHA was added to normal lymphocyte cultures at time zero and removed 
at 24 hours 46% of the control synthetic activity was observed at day 3, 
and significant amounts of synthesis were noted at later culture days, 4 
and 5. These findings are more consistent with those of Polgar et al.(139).
When CLL lymphocytes were exposed to PHA during the first 24 hours 
of culture, with media change and no subsequent readdition of PHA, 51% of 
the control DNA synthetic activity was observed at day 3, and subsequently 
only 12 to 15% of the control specific activities were observed at days 4 
to 7. This 51% activity observed at day 3 was the same percent (within 
error of the assay) found in normal lymphocyte cultures, using the same 
experimental conditions. When PHA was removed from the medium, 12 to 15% 
of the control DNA synthetic activity was observed, whereas in normal 
lymphocyte cultures, 37 to 64% was observed at days 4 and 5. Therefore, 
the possibility that the lymphocytes in the CLL population which were re­
sponding at days 5 to 7 were normal lymphocytes was quite unlikely.
Furthermore, in studies with CLL lymphocytes, removal of PHA at 
day 3, without its subsequent readdition, resulted in 71% of the control 
activity at day 5. These studies suggested that the cells which were syn­
thesizing maximal amounts of DNA at day 5 were a portion of the population 
stimulated by PHA between days 2 and 3 and were not the lymphocytes which 
were stimulated during the first 24 hours, as was characteristic of normal 
lymphocytes in cell culture.
The three-fold enhancement of DNA synthesis observed when PHA
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was added back at either days 3 or 4 could be due to a) exposure to PHA 
of a new population of more normal-like daughter cells, b) optimal concen­
trations of PHA added after autolysis of polymorphonuclear cells, or c) 
optimal concentrations of PHA present at a time when the CLL cell membrane 
or cellular activities or both have been conditioned to the medium and are 
metabolically stabilized. The first suggestion (a) is unlikely because 
the normal-like component probably represents only 10 to 20% of the total 
lymphocyte population and could not contribute 3-fold increases in total 
synthesis. The second suggestion (b) is also unlikely because preincuba­
tion of normal cells, before PHA addition, has not produced such marked in­
creases in DNA synthesis. The last suggestion (c) is supported by some 
experimental evidence. Studies in which CLL lymphocytes were maintained in 
culture for 3 days before adding PHA showed maximal DNA synthesis increased 
2.5-fold and occurred at day 5. The control cultures, without preincuba­
tion, exhibited maximal DNA synthesis at day 5. This significant increase 
in DNA synthesis was not observed when cells were preincubated for 24 or 
48 hours. The precise events occurring during this 72 hour period are not 
known, although it is possible that the lymphocyte undergoes some metabolic 
changes, as discussed later.
The second line of evidence to support the hypothesis of a "leu­
kemic" component of lymphocytes comes from the experiments showing the 
differential effects of isoproterenol on normal and CLL lymphocyte cultures. 
In the initial experiments, it was shown that 24 hour pretreatment with 
isoproterenol resulted in significant reductions in DNA synthesis with 
maximal synthesis occurring at day 4, whereas the non-isoproterenol treated 
control CLL cultures exhibited maximal DNA synthesis at days 5 to 7 after 
PHA addition. Control experiments with normal lymphocytes showed little or
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no effects when isoproterenol at the same concentrations which markedly af­
fected DNA synthesis in CLL lymphocytes was added to the medium either be­
fore or after addition of PHA.
The marked inhibition of DNA synthesis observed in these late- 
responding lymphocytes in CLL cultures, following treatment with the 
catecholamine isoproterenol, suggests that a metabolic alteration exists 
in this "leukemic" component of CLL lymphocytes. Further experimentation 
was undertaken to determine if there was a certain culture time or cell- 
state which was more sensitive to isoproterenol and the role of this cate­
cholamine in the metabolic activities of the CLL lymphocyte. It was shown 
in these studies that the CLL lymphocyte was most sensitive to isoproterenol 
during the initial 24 hours after PHA addition; furthermore, both 24 hours 
before and particularly after this initial 24 hour period (at 48 and 72 
hours) the effectiveness of the drug to inhibit DNA synthesis was reduced. 
This could be due to the PHA-induced changes in the membrane which occur 
soon after the addition of the mitogen (73). Possibly, the intracellular 
product of the catecholamine induced activation of adenyl cyclase, cyclic 
AMP, is present in either too great an amount or at an inopportune time 
and brings about a series of events which are lethal to the cell. These 
damaged cells then undergo autolysis, as observed by a loss of DNA, and any 
more normal-like cells which are present are destroyed due to the leaking 
lysosomal enzymes (132).
The intracellular, secondary messenger of catecholamine-induced 
activity, cyclic AMP, can be added exogenously to the lymphocyte cultures 
and should circumvent the adenyl cyclase-mediated production of cyclic AMP 
from its nucleoside triphosphate precursor, ATP. However, following cyclic 
AMP addition, less inhibition of DNA synthesis was obtained than with
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dlbutyryl cyclic AMP. This is consistent with two findings in the litera­
ture; first, the recent report (140) that calf serum contained phosphodi­
esterase activity cleaving cyclic AMP to adenosine monophosphate; secondly, 
a report suggesting that the membrane provided a barrier for the charged 
nucleotide (140). Both of these limitations for cyclic AMP were inconse­
quential when dibutyryl cyclic AMP was added to the cultured lymphocytes. 
From earlier studies it was asserted that the dibutyryl derivative was 
better-adapted for transport across the membrane from the extracellular to 
the intracellular spaces and was also more resistant to enzymic cleavage 
by phosphodiesterase (141). Our studies indicated that dibutyryl cyclic 
AMP produced the same inhibition, as observed with isoproterenol over a 
100-fold concentration range. This strongly supports the concept that iso­
proterenol increases intracellular cyclic AMP in CLL lymphocytes.
Cleavage of cyclic AMP to AMP-5’ by phosphodiesterase results in 
none of the original effectiveness in regulating many diverse cellular 
events. Phosphodiesterases are known from studies in brain (142) and liver 
(143) tissues to be found associated with the membrane or in the cytoplasm 
of the cells, as well as in calf serum (140). The methyl xanthines, spe­
cifically theophylline, inhibit one or more of these enzymes. When added 
to cultured CLL lymphocytes within 20 minutes after PHA addition, theo­
phylline had no inhibitory effect upon subsequent replication, however, 
when added in conjunction with isoproterenol, DNA synthesis was completely 
inhibited (99%). In these studies isoproterenol alone inhibited DNA syn­
thesis in CLL cultures 45%, whereas normal lymphocytes did not respond to 
isoproterenol, theophylline, or isoproterenol and theophylline additions, 
at these same concentrations. In agreement with the restriction found on 
timing, as found in experiments with isoproterenol treatment alone, the
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addition of isoproterenol with theophylline at day 2 was less damaging (50%) 
than either pretreatment for 24 hours or posttreatment within the first 24 
hours after PHA addition. Also, pretreatment with both compounds did not 
affect the synthesis at day 3 as greatly as treatment within the first 24 
hours. These studies strongly suggest that theophylline is potentiating 
the activity of isoproterenol in maintaining increased intracellular con­
centrations of cyclic AMP which are detrimental to cellular activities.
The differences in sensitivities of lymphocytes before and after PHA addi­
tion, also, suggest the occurrence of metabolic or membrane alterations 
during the course of cell culture.
One role of cyclic AMP in other tissues (101,102) is the regula­
tion of glycogen synthesis and degradation in order to meet cellular demands 
during periods of stress (103) or cell division (96). In the presence of 
elevated amounts of intracellular cyclic AMP, glycogen synthetase undergoes 
phosphorylation to a form which is dependent upon increased glucose-6- 
phosphate (101) within the cell to be active, therefore increases in cyclic 
AMP depress the synthesis of glycogen. At the same time, increases in intra­
cellular cyclic AMP bring about the conversion of phosphorylase b to the 
active form, phosphorylase a, which occurs by the specific activation of a 
protein kinase by cyclic AMP (104). It is conceivable that the acute sensi­
tivity of the CLL lymphocyte to isoproterenol is due to the phosphorolysis 
of stored glycogen, an event from which the leukemic lymphocyte may not be 
able to recover in order to continue the processes necessary for DNA syn­
thesis and cell division.
The early work of many groups of investigators (62,63,144) had clearly 
shown by semi-quantitative, histochemical methods that the non-stimulated 
CLL lymphocyte contained greater amounts of cytoplasmic glycogen than
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the normal lymphocyte. Further studies, reported by Seitz (64), using 
enzymic quantitation showed that normal lymphocytes contained 4.1 ±0.5 mg 
glycogen/ 10^^ cells, and CLL lymphocytes contained 7.0 ±0.7 mg glycogen/ 
10^^ cells. In the study presented here, glycogen was also quantitated and 
found to be 0.060 ug glycogen/ ug DNA (4.20 mg glycogen/ lO^^cells) to 0.130 
ug glycogen/ ug DNA (9.10 mg glycogen/ 10^^ cells) in normal lymphocytes, 
whereas the CLL lymphocytes were found to contain from 0.209 ug glycogen/ 
ug DNA (14.63 mg/10^^ cells) to 0.475 ug glycogen/ ug DNA (33.25 mg/10 
cells). The lower value for the amount of stored glycogen agreed with that 
found by Seitz (64), since a 2 to 7-fold increase was found in the CLL 
lymphocytes. There are several feasible reasons for the higher values 
found in the studies presented here. First, the methods of lymphocyte 
isolation and incubation could result in cellular trauma with loss of 
stored glycogen, thus resulting in lower values. Second, the amount of 
stored glycogen could be dependent upon the progression of the disease.
This interpretation is supported by the findings of Vereschagina (136) 
which indicated that as the disease progressed, noted by increasing WBC 
counts, an increase in the cellular content of glycogen in the freshly 
isolated lymphocytes occurred.
The stored glycogen which was found in the CLL lymphocyte there­
fore provides a specific site for isoproterenol-induced cyclic AMP activity. 
In the CLL lymphocytes, it was found that within 24 hours of isoproterenol 
addition to PHA-stimulated lymphocytes, there was a specific loss in gly­
cogen, as shown by the loss of PAS-stained material in the light photo­
micrographs. The phenomenon of isoproterenol-mediated loss of stored, 
cellular glycogen is further supported by Malamud (96) who demonstrated 
that administration of isoproterenol to mice initially increased the adenyl
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cyclase activity in salivary gland cells and subsequently decreased glyco­
gen content (95). In contrast to the CLL lymphocyte, however, the salivary 
gland cells resynthesized glycogen, replicated their cellular DNA and then 
divided.
Preliminary experiments, in this study, were undertaken to enzymi- 
cally quantitate glycogen in both normal and CLL lymphocytes after PHA— 
stimulation. In CLL lymphocytes there was a loss of glycogen during the 
first 48 hours after PHA addition, and it was only after the resynthesis 
of glycogen that DNA synthesis commenced. In contrast, however, the amount 
of glycogen in normal lymphocytes increased significantly during the initial 
48 hours after PHA-stimulation, followed by a plateau at days 2 and 3 and 
decreased thereafter.
The significance of the unusual accumulation of glycogen in the 
cytoplasm of the CLL lymphocyte is not fully understood at this time. It 
is possible to postulate that this storage of glycogen is either a primary 
or secondary defect which is associated with the disease. If the glycogen 
storage is the primary or fundamental defect in the leukemic process, one 
would expect that one of the enzymes either in the synthesis or the degra­
dation of glycogen is defective, and the glucose residues are inaccessable 
during events of cellular stress. In support of an alteration in the 
degradative pathway, Abell and Kamp (145) have found that phosphorylase a 
was not activated in CLL lymphocytes after PHA-stimulation, whereas in 
normal lymphocyte cultures phosphorylase a activity was increased markedly 
after PHA-s timulation. This type of enzymic defect has been clearly demon­
strated in six of the nine types of glycogen storage diseases. In these 
six forms of disease (146,147,148,149,150,151) an enzymic defect was demon­
strated in one or more of the enzymes involved in the degradation of
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glycogen, and in the other three types of glycogen storage diseases enzy­
matic defects were demonstrated in the synthesis (152) of glycogen or the 
transport (153) and metabolism (154) of glucose. These diseases have as 
the hallmark of diagnosis increased amounts of glycogen in either liver or 
muscle cells, and of special interest were reports which indicated that the 
same enzymic defects found in the liver cells were also found in the leuko­
cytes (105) of the affected patients. Although specific enzymic defects 
are known to occur in glycogen storage diseases, the ramifications of these 
defects in cellular metabolism are not fully understood, especially in 
suggesting a role for the altered metabolism in the affected leukocytes.
It is also possible that in CLL the accumulation of glycogen is a 
secondary defect, and therefore one could hypothesize that an alteration 
occurs at some metabolic point quite distant from the synthesis or degrada­
tion of glycogen. The accumulation of glycogen could occur if a product of 
altered metabolism were either accumulated or excessively utilized and thus 
bring about an alteration in the control of glycogen metabolism. It would 
be the "distant metabolic alteration" which would be the deleterious event 
in the leukemic process with the unusual storage of glycogen as a "symp­
tom" of this defect.
The studies presented here strongly suggest that the relationships 
of increased glycogen content and delayed responsiveness to PHA with the 
progression of the disease are important features to be considered in 
elucidating the precise alteration in CLL lymphocytes. Further experimen­
tation should be undertaken to measure the enzymes associated with the syn­
thesis of glycogen, and also, in addition to phosphorylase a, the enzymes 
involved in the degradation of cytoplasmic glycogen. In differentiating 
primary from secondary mechanisms, it would be appropriate to study the
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enzymes which are active at control points in metabolic processes.
Another significant finding of this study is the acute sensitivity 
of the CLL lymphocyte to isoproterenol, the bronchodilator, which is exten­
sively used in medical practice. It is conceivable that a structurally- 
related compound which does not have the adverse cardiac effects would be 
quite useful in the treatment of CLL.
In conclusion, this study has answered the questions which were 
proposed at the outset. First, a cell culture system has been developed 
which supported maximal proliferation of the CLL lymphocyte, and therefore 
a study of the biochemical activities associated with proliferation was 
feasible. Second, it was found that while lymphocytes from CLL patients 
did respond to PHA with maximal DNA synthesis occurring to an extent com­
parable with normal lymphocytes, the response was delayed one to four days. 
Also, this delay in maximal DNA synthesis was correlated with the progres­
sion of the disease distinguished clinically as increasing peripheral leuko­
cyte counts. Third, results of studies on the mode of action of the cate­
cholamine isoproterenol strongly suggested that intracellular cyclic AMP 
was involved in the inhibition of DNA synthesis in CLL lymphocytes.
Fourth, it was shown that cyclic AMP presumably caused the phosphorolysis 
of the accumulated glycogen in the CLL lymphocytes. Fifth, the unusual 
glycogen of the CLL lymphocytes was examined by electron microscopy, iso­
lated and characterized chemically and quantitated in both the normal and 
CLL lymphocytes in the resting and PHA-stimulated states.
CHAPTER V
SUMMARY
Human peripheral blood lymphocytes from both normal donors and 
patients with chronic lymphocytic leukemia (CLL) were maintained in a cell 
culture system and studied in both the resting and mitogen-stimulated states. 
These CLL lymphocytes responded to PHA, a mitogenic extract of Phaseolus 
vulgaris, with maximal DNA synthesis occurring 5 to 7 days after PHA addi­
tion to the cultures. This is 1 to 4 days later than the time of maximal 
response in normal lymphocytes, at day 3 or 4.
It was also found that the portion of cells which responded at 
days 3 and 4 in the CLL lymphocyte cultures reflected a more normal-like 
population of lymphocytes, biochemically different from the cells demon­
strating maximal DNA synthesis at days 5 to 7. The "leukemic" component 
of the CLL lymphocyte population was uniquely sensitive to additions of 
isoproterenol, presumably through an adenyl cyclase-mediated increase in 
intracellular cyclic AMP. This interpretation was supported by two lines 
of evidence. First, the same extent of inhibition produced by isoproterenol 
was demonstrated with the N^-2'-0-dibutyryl derivative of cyclic AMP, over 
a 100-fold concentration range. Second, theophylline, a methyl xanthine 
reported to inhibit the phosphodiesterase catalyzed cleavage of cyclic AMP 
to AMP-5*, potentiated the effectiveness of low concentrations of isopro­
terenol in inhibiting DNA synthesis.
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One effect of isoproterenol in CLL lymphocytes was shown by 
histochemical techniques to involve the phosphorolysis of stored glycogen. 
The ultrastructure of this glycogen, not observed in normal lymphocytes, 
was examined by electron microscopy and was unusual in appearance. These 
particles were large, 0.2 to 0.5 microns in diameter, and membrane-bound. 
The glycogen from them was isolated and found to sediment at a density of
1.64, and electron micrographs of the isolated material (1,64) indicated 
that these were beta-particles.
Thus, these studies have elucidated several biochemical differ­
ences between CLL and normal lymphocytes. The development of a culture 
system and the elucidation of the interrelationships of altered nucleic 
acid synthesis, glycogen metabolism, and the role of cyclic AMP indicate 
new directions of investigation to broaden the knowledge of basic cellular 
mechanisms and to suggest potential new methods of treatment for this 
disease. ~
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